Terms: = Cervical cancer AND Neurokinin AND Treatment
4 results:
1. Control and Risk Factors of Nausea and Vomiting in Patients With cervical cancer Receiving Radiotherapy.
Uno A; Yamamoto S; Iihara H; Fujii H; Makita C; Hayasaki Y; Ueda Y; Ito M; Takenaka M; Kumano T; Mori M; Yasue M; Kato-Hayashi H; Kobayashi R; Morishige KI; Matsuo M; Hayashi H; Suzuki A
Anticancer Res; 2022 Jun; 42(6):3117-3123. PubMed ID: 35641271
[TBL] [Abstract] [Full Text] [Related]
2. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
[TBL] [Abstract] [Full Text] [Related]
3. Prescription of Prophylactic Antiemetic Drugs for Patients Receiving Chemotherapy With Minimal and Low Emetic Risk.
Okuyama A; Nakamura F; Higashi T
JAMA Oncol; 2017 Mar; 3(3):344-350. PubMed ID: 27812688
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.
Ruhlmann CH; Christensen TB; Dohn LH; Paludan M; Rønnengart E; Halekoh U; Hilpert F; Feyer P; Kristensen G; Hansen O; Keefe D; Herrstedt J
Lancet Oncol; 2016 Apr; 17(4):509-518. PubMed ID: 26952945
[TBL] [Abstract] [Full Text] [Related]
